This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omega Therapeutics, Inc. (OMGA) Surges 19.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Pfizer (PFE) Gets FDA Acceptance for Braftovi + Mektovi sNDAs
by Zacks Equity Research
FDA accepts Pfizer's (PFE) sNDAs seeking approval of Braftovi + Mektovi for BRAF V600E-mutant non-small cell lung cancer.
J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits
by Zacks Equity Research
To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.
Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why
by Zacks Equity Research
Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.
The Zacks Analyst Blog Highlights Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys
by Zacks Equity Research
Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys are included in this Analyst Blog.
Top Stock Reports for Berkshire Hathaway, Roche & Thermo Fisher Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Roche Holding AG (RHHBY) and Thermo Fisher Scientific Inc. (TMO).
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly
by Zacks Equity Research
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
by Kinjel Shah
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device
by Zacks Equity Research
Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.
Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee
by Zacks Equity Research
Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK
by Kinjel Shah
FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.
Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study
by Zacks Equity Research
Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.
Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
by Zacks Equity Research
Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
by Zacks Equity Research
The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
by Zacks Equity Research
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.
Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down
by Zacks Equity Research
Halozyme Therapeutics (HALO) reports mixed fourth-quarter results. Stock is down in the after-market hours in response to the earnings results.
Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA
by Zacks Equity Research
The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.
Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.
Pharma Stock Roundup: FDA Nod to PFE Cibinqo for Adolescents, Updates From NVO, RHHBY
by Kinjel Shah
FDA approves Pfizer's (PFE) Cibinqo for adolescent patients. Roche (RHHBY) announces new positive data from phase III studies on Vabysmo for vision loss associated with retinal vein occlusion.
Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.
Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO
by Kinjel Shah
AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.
Will Biogen (BIIB) Beat Estimates This Earnings Season?
by Zacks Equity Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.